Shandong Xinhua Secures Key Drug Application Approval
Company Announcements

Shandong Xinhua Secures Key Drug Application Approval

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.

Shandong Xinhua Pharmaceutical Company Limited has announced the successful approval of a supplementary drug application for its pentoxifylline injections by the National Medical Products Administration. The approval signifies the company’s right to change the marketing license holder for the product. Additionally, the company disclosed a technology transfer contract with Suzhou Langke Biotechnology Co., Ltd., transferring the rights and interests related to the marketing and production technology of the drug.

For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharmaceutical Announces December EGM
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharma Secures Key Drug Approval
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua’s Generic Drug Receives Key Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App